Avalyn Pharma Quarterly Cash Flow Statement
NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.76+0.04 (+0.16%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalyn Pharma free cash flow
In the quarter ended Jun 30, 2026, Avalyn Pharma generated -$26.1 million of operating cash flow and spent $269,000 on capital expenditures. That left free cash flow of -$26.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Avalyn Pharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -28.93M | -26.87M | -20.19M | -17.50M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 110.00K | 63.00K | 9.00K | 10.00K |
| Stock-Based Compensation | 2.79M | 1.19M | 1.13M | 543.00K |
| Change in Working Capital | -184.00K | -3.58M | -893.00K | -1.50M |
| Operating Cash Flow | -26.08M | -29.89M | -20.70M | -19.27M |
| Capital Expenditures | -269.00K | -318.00K | 0 | -8.00K |
| Investing Cash Flow | -118.71M | 55.02M | -36.69M | 24.12M |
| Financing Cash Flow | 316.67M | 14.86M | 89.88M | 0 |
| Free Cash Flow | -26.34M | -30.21M | -20.70M | -19.28M |
This table shows 4 quarterly periods of Avalyn Pharma's cash flow statement, from Q2 2026 back to Q? 2025, across 9 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AVLN's reporting calendar. What is a cash flow statement?